OC treatments were administered in this study either alone, or after completing presurgical (neoadjuvant) regimens with the dual EGFR–HER2 inhibitor lapatinib (LP), in a test system intended to model HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.